CRIS Current Research Information System

DI MARCO, MARIACRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.429
EU - Europa 5.702
AS - Asia 5.379
AF - Africa 585
SA - Sud America 370
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 6
AN - Antartide 1
Totale 19.478
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.371
CN - Cina 1.780
SG - Singapore 1.745
GB - Regno Unito 1.205
IT - Italia 1.196
SE - Svezia 747
VN - Vietnam 742
DE - Germania 690
HK - Hong Kong 422
IN - India 310
RU - Federazione Russa 278
CH - Svizzera 273
BR - Brasile 268
IE - Irlanda 240
FR - Francia 233
NL - Olanda 206
UA - Ucraina 206
CI - Costa d'Avorio 152
KR - Corea 136
TG - Togo 129
ZA - Sudafrica 115
FI - Finlandia 103
EE - Estonia 86
NG - Nigeria 83
SC - Seychelles 82
AT - Austria 61
JO - Giordania 54
BG - Bulgaria 53
JP - Giappone 53
AR - Argentina 36
ID - Indonesia 36
BE - Belgio 35
CA - Canada 35
EC - Ecuador 21
PL - Polonia 20
MX - Messico 17
TR - Turchia 17
ES - Italia 16
IR - Iran 16
CL - Cile 15
BD - Bangladesh 12
GR - Grecia 10
HR - Croazia 9
IQ - Iraq 9
LB - Libano 9
LT - Lituania 9
CO - Colombia 8
PY - Paraguay 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 6
PE - Perù 6
AU - Australia 5
EG - Egitto 5
PT - Portogallo 5
UY - Uruguay 5
CZ - Repubblica Ceca 4
NI - Nicaragua 4
PK - Pakistan 4
RO - Romania 4
DK - Danimarca 3
EU - Europa 3
KZ - Kazakistan 3
NP - Nepal 3
RS - Serbia 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BY - Bielorussia 2
CM - Camerun 2
DZ - Algeria 2
HU - Ungheria 2
MA - Marocco 2
MU - Mauritius 2
MY - Malesia 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
AQ - Antartide 1
AZ - Azerbaigian 1
BO - Bolivia 1
BW - Botswana 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GT - Guatemala 1
IL - Israele 1
KH - Cambogia 1
LY - Libia 1
ML - Mali 1
MR - Mauritania 1
NZ - Nuova Zelanda 1
PH - Filippine 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
Totale 19.478
Salva come PNG Salva come JPEG
Città #
Singapore 1.108
Southend 1.055
Ashburn 850
Chandler 694
Fairfield 682
Hong Kong 418
Dallas 321
Houston 321
Hefei 313
Santa Clara 309
Princeton 285
Woodbridge 275
Bern 266
Wilmington 261
Beijing 260
Dong Ket 256
Seattle 244
Dublin 240
Ann Arbor 231
Bologna 227
Cambridge 211
Boardman 162
Abidjan 152
New York 147
Seoul 132
Lomé 129
Nanjing 111
Los Angeles 110
Westminster 109
Jacksonville 108
Padova 98
Ho Chi Minh City 96
Hanoi 83
Berlin 82
Helsinki 80
Turin 76
Milan 72
Jinan 68
Abeokuta 65
Medford 65
Shenyang 65
Florence 60
Redondo Beach 58
Rome 54
Amman 53
Sofia 53
Redmond 51
Tokyo 49
Buffalo 48
Tianjin 47
Munich 46
San Diego 46
Saint Petersburg 45
Frankfurt am Main 43
Hebei 40
Nanchang 36
Changsha 35
Shanghai 33
Dearborn 32
Brussels 31
Guangzhou 31
Des Moines 30
Mülheim 30
Bengaluru 29
Falkenstein 29
Falls Church 29
São Paulo 29
Vienna 28
Nuremberg 26
Tongling 26
Hangzhou 25
Bremen 24
Jiaxing 23
Jakarta 22
Taiyuan 21
Brooklyn 20
Redwood City 20
Yubileyny 20
London 19
Zhengzhou 19
Bühl 18
Düsseldorf 17
Fremont 17
Haiphong 17
Toronto 17
Chicago 16
Phoenix 16
Olalla 15
Washington 15
Forlì 14
Ravenna 14
Hyderabad 13
Kunming 13
Kyiv 13
Lappeenranta 13
Norwalk 13
Chennai 12
Kuban 12
Leawood 12
Ningbo 12
Totale 12.486
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 400
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 269
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 237
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 233
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: a single center prospective, randomized controlled study. 231
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 227
Adjuvant chemoradiation in pancreatic cancer: Impact of radiotherapy dose on survival 218
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 216
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 212
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 209
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 194
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 193
Comparing recist and Choi’s criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer 191
Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. 189
Mutational burden of resectable pancreatic cancer by whole-transcriptome and whole-exome sequencing could predict a poor prognosis 188
β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer 182
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 181
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 180
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 178
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 173
The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study 173
Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression 172
In Reply 169
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 169
Multicolour versus monocolour inking specimens after pancreaticoduodenectomy for periampullary cancer: A single centre prospective randomised clinical trial 168
Treatment of colorectal cancer liver metastases 167
Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 165
Branch duct intraductal papillary mucinous neoplasm: validation of Fukuoka 2012 guidelines using a systematic review and meta-analysis 164
Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1) 164
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre 163
Clinical impact of nonselective beta-blockers on survival in patients with pancreatic cancer- revival of well known drugs? 163
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 161
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study 159
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 159
Comparing RECIST and Choi's Criteria After Neoadjuvant Chemoradiotherapy in Patients with Resectable Pancreatic Cancer 158
Discovery of new potential actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 158
State of the art biological therapies in pancreatic cancer 157
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 156
GemOx and Ovarian Pancreatic Cancer Metastasis (PC) 156
Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients 155
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 155
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 154
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 153
Advanced pancreatic cancer (APC) A monocenter experience in 53 patients: is it possible a second line treatment? 151
Prospective validation of a preoperative risk score model based on pancreatic texture to predict postoperative pancreatic fistula after pancreaticoduodenectomy. 150
Pancreatic ductal adenocarcinoma associated with autoimmune pancreatitis. 150
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 146
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 146
Risk Factors in Resected Pancreatic Cancer. A Single Centre Experience 145
Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses 145
Capecitabine(CAP) based regimens vs infusional 5FU/AF in metastatic colorectal cancer cost/effectivness: the differences across the atlantic ocean 144
Intraductal papillary mucinous neoplasms: the Bologna experience. Lessons learned from 357 cases observed in a tertiary care center 144
Intraductal papillary mucinous neoplasms: the bologna experience. Lessons learned from 357 cases observed in a tertiary care center 143
Pancreatic cyst surveillance imposes low psychological burden 142
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 142
Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study 141
Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets 140
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 137
CIRCULATING METALLOPROTEINASE-3 AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 IN PATIENTS WITH DUCTAL PANCREATIC NEOPLASMS 137
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib 137
Intervento educativo rivolto a giovani fumatori della scuola secondaria di secondo grado 136
Preoperatory Gemcitabine and Oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma 134
The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study 134
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? 132
Hedgehog Signaling: from the Cuirass to the Heart of Pancreatic Cancer 131
Advanced pancreatic cancer (apc); a Monocenter experience in 53 patients. It is possible a second line treatment? 129
Gemox in combination witherlotinib (E) in pancreatic cancer (PC). 129
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. 129
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 129
EXOCRINE-ENDOCRINE PANCREATIC CANCER AND alpha-FETOPROTEIN 128
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 128
Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1) 128
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 128
Intraductal Papillary Mucinous Neoplasms: The Bologna Experience 126
Risk Factors for Malignancy of Branch-Duct Intraductal Papillary Mucinous Neoplasms: A Critical Evaluation of the Fukuoka Guidelines With a Systematic Review and Meta-analysis 126
External validation of nomogram for predicting malignant intraductal papillary mucinous neoplasm (IPMN): from the theory to the clinical practice using the decision curve analysis model 126
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? 125
Locally Advanced Pancreatic Cancer: Is There a Role for Neoadjuvant Chemo-Radiation? A Case Report and Literature Review 124
Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients. 124
Cost of management of completely implantable catheters (CIC) in patients treated for advanced colorectal cancer 123
Useful of Choi’s criteria after neoadjuvant chemoradiotherapy in patients with resectable pancreatic cancer. 123
Prognostic factors for recurrence in resected pancreatic adenocarcinoma: a single center experience 123
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 123
Long-Term Survival After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Case Report 122
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOINSTITUTIONAL EXPERIENCE 121
Comparing RECIST and Choi’s Criteria to Evaluate Radiological Response to Chemotherapy in Patients with Advanced Pancreatic Cancer 121
Is safe the laparoscopic approach in distal pancreatectomy for ductal adenocarcinoma? Systematic review and meta-analysis 121
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 120
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 120
Massively Parallel Sequencing Analysis of Genetic Alterations Carried by Pancreatic Adenocarcinoma 119
Is total pancreatectomy as feasible, safe, efficacious, and cost-effective as pancreaticoduodenectomy? A single center, prospective, observational study 119
Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results - a single‑center experience 118
Hacking pancreatic cancer: Present and future of personalized medicine 118
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice—a fifteen-year journey at a tertiary referral centre 117
Immunonutrition in patients who underwent major abdominal surgery: A comprehensive systematic review and component network metanalysis using GRADE and CINeMA approaches 117
Prognostic factors in resected pancreatic cancer:a single centre experience 117
The follow-up issues: from the necessity to the opportunity 117
Erratum: β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer (Cancer Cell (2018) 33(1) (75–90.e7), (S153561081730510X) (10.1016/j.ccell.2017.11.007)) 117
null 117
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 116
Totale 15.414
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.849
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.849
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.305 0 0 0 0 0 84 117 139 174 104 107 580
2021/20222.699 194 106 96 201 228 125 66 179 151 264 651 438
2022/20233.334 302 476 178 370 227 254 51 192 499 127 305 353
2023/20241.039 88 130 84 95 81 270 50 62 25 69 52 33
2024/20253.438 172 429 275 240 474 167 273 192 53 333 173 657
2025/20264.041 716 731 870 624 873 227 0 0 0 0 0 0
Totale 19.968